Search PubMed⌕ Search

Biomedical subjects

Z Fuks

Publications and source records attributed to Z Fuks.

308 records · Page 18Linked to original sources

Intravenous basic fibroblast growth factor protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo.

PURPOSE: We evaluated the therapeutic potential of intravenously injected basic fibroblast growth factor against the lethal syndromes associated with irradiation of intrathoracic organs and assessed whether such protection might be associated with inhibition of programmed cell death (apoptosis) in the exposed tissues. MATERIALS AND METHODS: C3H/HeJ and C3H/scid mice received either whole-chest, mediastinal, or bilateral lung irradiation. Human recombinant basic fibroblast growth factor was injected intravenously at doses of 400 ng immediately before and after irradiation, and then at 1 hour and 2 hours later. Time-adjusted survival was calculated from the date of irradiation by the product-limit Kaplan-Meier method. Detection of apoptotic changes in paraffin sections was performed by the DNA terminal transferase nick-end translation method. RESULTS: Basic fibroblast growth factor protected the lungs but not other intrathoracic organs against radiation-induced damage. When radiation was restricted to the lungs, the LD50/180 from radiation pneumonitis was 20.75 Gy and increased to 23.0 Gy in basic fibroblast growth factor-treated mice. When the whole thorax was irradiated, basic fibroblast growth factor partially protected against pneumonitis at the low range of radiation doses (< or = LD50/180), but failed to confer protection at higher doses, nor did it protect against lethal radiation esophagitis. Staining for the presence of apoptotic nuclei revealed time- and radiation dose-dependent development of apoptosis in endothelial cells of the pulmonary capillary network, endocardium, and mesothelial cells of the pleura and pericardium. Although basic fibroblast growth factor inhibited apoptosis in the microvascular endothelium and the endocardium, it had no effect on apoptosis in the serosal mesothelium of the pleura and pericardium. CONCLUSIONS: Intravenous basic fibroblast growth factor protects against the apoptotic microvascular component of early-phase radiation pneumonitis but may have no effect on other elements of the primary damage produced by radiation in the lungs and other intrathoracic organs. Understanding the patterns and temporal evolution of radiation-induced apoptosis and basic fibroblast growth factor-mediated antiapoptotic effects in thoracic organs and tumors may offer opportunities for pharmacologic intervention in the radiotherapeutic management of primary and metastatic lung tumors.

Animals↗

The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.

PURPOSE: To evaluate the acute morbidity, late toxicity, and response to treatment in patients with prostate cancer treated on a phase I dose-escalation study with three-dimensional conformal radiotherapy. METHODS: A group of 432 patients with stages T1c-T3 prostate cancer were treated with three-dimensional conformal radiotherapy targeting the prostate and seminal vesicles, but effectively excluding the surrounding normal tissue structures from the high-dose volume. A minimum tumor dose of 64.8 to 66.6 Gy was given to 89 patients (20%), 70.2 Gy to 199 patients (46%), 75.6 Gy to 98 patients (23%), and 81.0 Gy to 46 patients (11%). RESULTS: Treatment was well tolerated, and the acute toxicities and long-term complications observed were of minimal severity (grade 1 or 2) regardless of dose. Acute grade 2 rectal symptoms were observed in 15% of patients, whereas 40% developed grade 2 urinary symptoms. Among patients who received from 64.8 to 70.2 Gy, the 2-year actuarial likelihood of grade 2 late toxicity was 2% for rectal and 1% for urinary complications, compared to 11% and 5%, respectively, for those treated with doses ranging from 75.6 to 81 Gy. Only three patients (0.7%) have so far developed severe (grade 3 or 4) late urethral or rectal complications. The rate of prostate-specific antigen normalization from abnormal pretreatment levels to a value of < or = 1.0 ng/mL was used as an endpoint to evaluate the initial response to treatment. When the analysis was restricted to patients with pretreatment prostate-specific antigen levels of < or = 20 ng/mL, patients who received 70.2 Gy had a significantly higher rate of prostate-specific antigen normalization than patients who received 64.8 to 66.6 Gy. Evaluation of the prostate-specific antigen response at 75.6 Gy and 81.0 Gy was not possible because of the short follow-up time in many of these patients. CONCLUSIONS: Three-dimensional conformal radiotherapy technique has made it possible safely to escalate radiation doses to unprecedented levels in patients with prostatic cancer. Preliminary evidence for an improved initial prostate-specific antigen response with higher doses indicates a potential for an improved therapeutic ratio with the three-dimensional conformal radiotherapy approach.

Adenocarcinoma↗